Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Veliparib Combination Plus Maintenance Extends PFS For Advanced Serous Ovarian Carcinoma

Use of veliparib alongside chemotherapy and continuing with the PARP inhibitor as a maintenance therapy has improved progression-free survival for advanced ovarian cancer
15 Oct 2019
Anticancer Agents;  Ovarian Cancer;  Personalised/Precision Medicine
By Lynda Williams, Senior medwireNews Reporter

medwireNews: The VELIA/GOG-3005 trial results support the use of veliparib in combination with carboplatin and paclitaxel for the first-line treatment of stage III–IV, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, followed by maintenance therapy with the PARP inhibitor.

The phase III findings were published in The New England Journal of Medicine to coincide with a presentation at the ESMO 2019 Congress in Barcelona, Spain, by lead investigator Robert Coleman, from the University of Texas MD Anderson Cancer Center in Houston, USA.

The trial recruited 1140 participants.Patients were randomly assigned to receive veliparib 150 mg twice daily alongside six 21-day cycles of carboplatin to area under the curve of 6 mg/mL per min every 3 weeks plus paclitaxel given at a dose of 175 mg/m2 every 3 weeks or 80 mg/m2 weekly, followed by 30 cycles of veliparib maintenance; or to receive chemotherapy plus placebo, followed by placebo maintenance; or to receive chemotherapy plus veliparib followed by placebo maintenance.

For the subgroup of 297 patients with a BRCA1/2 mutation, median progression-free survival (PFS) was 34.7 months for those given chemotherapy plus veliparib, followed by veliparib maintenance, and this was significantly longer than the 22.0 months for those patients who instead received chemotherapy plus placebo and placebo maintenance, with a HR for death or progression of 0.44 in favour of the PARP inhibitor.

The PFS benefit with veliparib throughout over placebo was also found for the 627 patients with homologous recombination deficiency (HRD)-positive disease, including those with BRCA1/2 mutations, at 31.9 versus 20.5 months and a HR of 0.57.

And veliparib combination and maintenance therapy continued to offer a significant PFS benefit within the intention-to-treat population, including all patients regardless of BRCA and HRD status, at 23.5 months with and 17.3 months without veliparib use, with a HR of 0.68.

However, the investigators say that “[t]he independent value of adding veliparib during induction therapy without veliparib maintenance was less clear”.

Analysis of the 383 patients who received veliparib during chemotherapy but placebo during maintenance gave a median PFS of 21.1 months for the BRCA1/2 mutation subgroup (HR=1.22 vs placebo), 18.1 months for the HRD subgroup (HR=1.10 vs placebo), and 15.2 months for the intention-to-treat population (HR=1.07).

“Inferences drawn from the absence of improvement in progression-free survival in the veliparib-combination-only group may suggest that the benefit from veliparib is related to its use as maintenance therapy”, the authors hypothesize, but admit the study design does not test this hypothesis.

At the time of analysis, the overall survival data for the study cohorts were not mature, they add.

Robert Coleman and team report comparable rates of adverse events (AEs) in the intention-to-treat analysis of patients given veliparib throughout versus placebo, but note the PARP inhibitor used throughout treatment was associated with greater gastrointestinal toxicity and higher rates of grade 3–4 thrombocytopenia (28 vs 8%) and anaemia (38 vs 26%).

Nevertheless, the researchers highlight that these haematological events “were significantly lower during the maintenance phase, in which less than 8% of the patients in the veliparib-throughout group had a grade 3 or 4 event.” 

“In general, the incidence of toxic effects with veliparib monotherapy was lower than has been reported with other PARP inhibitors,” they add.

 

References 

Coleman RL, Fleming GF, Brady MF, et alVeliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer.N Engl J Med; Advance online publication 28 September 2019.DOI: 10.1056/NEJMoa1909707 

Coleman RL, Fleming GF, Brady MF, et alVELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC).ESMO 2019 Congress; Barcelona, Spain: 27 September–1 October.LBA3

Last update: 15 Oct 2019

medwireNews (www.medwireNews.com) is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.